Save
EFFICACY AND TOLERANCE OF PARECOXIB FOR PREVENTION OF CATHETER-RELATED BLADDER DISCOMFORT IN PATIENTS UNDERGOING CATHETERIZATION AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR: PRELIMINARY RESULTS
ESRA Academy. AHMED A. Sep 8, 2016; 138565
Topic: PAIN THERAPY (ACUTE - CHRONIC)
ABBES AHMED
ABBES AHMED

Access to Premium content is currently a membership benefit.


Click here to join ESRA or renew your membership.

Abstract
Discussion Forum (0)
Rate & Comment (0)
Background and Aims:

Catheter-related bladder discomfort (CRBD) is defined as an urge to void or discomfort in the supra-pubic region; reported postoperatively in patients who have had urinary catheterization intra-operatively. In the present study, we evaluated Parecoxib (P) for preventing CRBD in patients undergoing catheterization after transurethral resection of bladder tumor (TURBT).

Methods:

Thirty consecutive adult patients, ASA physical status I and II, undergoing elective TURBT under spinal anesthesia were randomly allocated into 2 groups: Group (C) patients received placebo and group (P) patients received 40 mg of IV parecoxib 30 min before surgery. Lumber subarachnoid block was administered with 2 ml 0.5% hyperbaric bupivacaine and 2.5 µg Sufentanyl. Intra-operatively, urinary catherization was performed with a 16 Fr Foley’s catheter, and the balloon was inflated with 10 ml distilled water. The CRBD was assessed at 0, 1, 2, and 6 h after patient’s arrival in the PACU. Severity of CRBD was graded as none, mild, moderate and severe. Pearson's Chi-square and Fisher's Exact tests were used. P < 0.05 was considered significant.

Results:

Patient characteristics were similar between groups (Table 1). Parecoxib reduced the incidence (P=0.024) of CRBD compared with the control group at 4 h in the postoperative period (Table 2). Parecoxib also decrease postoperative pain scores and requirements of rescue analgesics. 


 

Conclusions:

We suggest that Parecoxib is an effective and safe modality for the treatment of bladder discomfort in the postoperative setting. These preliminary results will require confirmation in a larger number of patients. This trial was registered at ClinicalTrials.gov, number: NCT02729935
 

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings